Development of an Oxygen Carrier for Use in Hemorrhagic Shock Resuscitation

Abstract

The FDA is promoting studies as an immediate reaction to the COVID-19 emergency. In response to this call, Biologics Consulting and VTB finalized the FDA Pre-IND briefing document to include Pre-clinical, CMC (Chemistry Manufacturing and Controls) and Clinical Sections. VTB held the FDA Pre-IND meeting with an OxyBridge Briefing Document with an indication to treat Acute Respiratory Distress Syndrome (ARDS). However, it is recognized that the CMC and pre-clinical work applies equally to other indications such as Hemorrhagic Shock.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Aug 26, 2021
Accession Number
AD1153575

Entities

People

  • Joseph Tucker
  • Kim Vandegriff
  • Phil Farabaugh
  • W. R. Light

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Abstracts
  • Acute Respiratory Distress Syndrome
  • Biological Products
  • Biomedical Research
  • Biotechnology
  • Blood
  • Blood Volume
  • Chemistry
  • Contracts
  • Covid-19
  • Department Of Defense
  • Education
  • Electronic Mail
  • Governments
  • Health Services
  • Hemorrhage
  • Hemorrhagic Shock
  • Maryland
  • Materials
  • Medical Personnel
  • Patents
  • Standards
  • Technology Transfer
  • United States

Fields of Study

  • Medicine

Readers

  • Clinical Trial Research.
  • Immunology and Pathology
  • Trauma Surgery or Emergency Medicine.